後天性A型血友病

10.6666/ClinMed.2017.80.4.111

陳玟均；陳三奇

後天性A型血友病(acquired hemophilia A) ； 第八凝血因子抑制物(factor VIII inhibitor) ； 血漿混合檢驗(mixing study) ； Bethesda assay ； 抗磷脂症後群(antiphospholipid syndrome)

臨床醫學月刊

80卷4期（2017 / 10 / 27）

601 - 606

繁體中文

後天性A型血友病(acquired hemophilia A)是很難診斷，且容易被延誤的疾病，約有一半的病患發病原因不明。其發生率相當低，每年每百萬人約只有1.5人被診斷，其中以75-80歲的老人家最為常見，臨床表現以不正常出血為主。本篇文章報告一個後天性A型血友病的臨床案例，並介紹這個疾病的臨床表現、診斷流程、治療方式及預後。

1. Amano, K,Seita, I,Higasa, S(2016).Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.Haemophilia,23,50-58.
2. Ame, PR,Graf, M,Archer, J(2015).Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.Clin Appl Thromb Hemost,21,149-154.
3. Bittinga, R,Bent, S,Li, Y(2009).The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis.Blood Coagul Fibrinolysis,20,517-523.
4. Collins, P,Macartney, N,Davies, R(2004).A population based, unselected, consecutive cohort of patients with acquired haemophilia A.Br J Haematol,124,86-90.
5. Collins, PW,Chalmers, E,Hart, D(2013).Diagnosis and management of acquired coagulation inhibitors a guideline from UKHCDO.Br J Haematol,162,758-773.
6. Collins, PW,Hirsch, S,Baglin, TP(2007).Acquired hemophilia A in The United Kingdom: a 2-year national surveillance study by t he United Kingdom Haemophilia Centre Doctors' Organisation.Blood,109,1870-1877.
7. Franchini, M,Mannucci, PM(2013).Acquired haemophilia A: a 2013 update.Thromb Haemost,110,114-120.
8. Hay, CR(1998).Factor VIII inhibitors in mild and moderate-severity haemophilia A.Haemophilia,4,558-563.
9. Keeling, D,Mackie, I,Moore, GW(2012).Guidelines on the investigation and management of antiphospholipid syndrome.Br J Haematol,157,47-58.
10. Knoebl, P,Marco, P,Baudo, F(2012).Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).J Thromb Haemost,10,622-631.
11. Kruse-Jarres, R,St-Louis, J,Greist, A(2015).Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.Haemophilia,21,162-170.
12. Lottenberg, R,Kentro, TB,Kitchens, CS(1987).Acquired hemophilia: a natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy.Arch Intern Med,147,1077-1081.
13. Shetty, SD,Ghosh, K(2015).Challenges and open issues in the management of acquired hemophilia A (AHA).Blood Cells Mol Dis,54,275-280.
14. Shima, M,Lillicrap, D,Kruse-Jarres, R(2015).Alternative therapies for the management of inhibitors.Haemophilia,22,36-41.
15. Tarantino, MD,Cuker, A,Hardesty, B(2016).Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.Haemophilia,23,25-32.
16. Zakas, PM,Vanijcharoenkarn, K,Markovitz, RC(2015).Expanding The ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.J Thromb Haemost,13,72-81.